Sichuan Kelun-Biotech at 4-week high on positive lung cancer trial with Merck

Merck & Co

22/05/2026 06:07

** Hong Kong shares of Sichuan Kelun-Biotech Biopharmaceutical 6990.HK jump 10.1% to HK$499.6, their highest level since April 22

** Stock of key shareholder Sichuan Kelun Pharmaceutical 002422.SZ surge 9.8% to 35.57 yuan, highest point since April 17

** Sichuan Kelun-Biotech said on Thursday its experimental treatment combined with partner Merck's MRK.N Keytruda improved progression-free survival in patients with advanced lung cancer, meeting the main goal of a late-stage study

** The trial tested the drug, sacituzumab tirumotecan or sac-TMT, in combination with cancer therapy Keytruda as a first-line treatment for patients with advanced non-small cell lung cancer, against Keytruda alone

** YTD, Hong Kong stock up 20.9%, shares of Shenzhen-listed parent up 19.4%

(Reporting by Donny Kwok)

((donny.kwok@thomsonreuters.com))